260 related articles for article (PubMed ID: 19577816)
1. Pemetrexed in the treatment of advanced non-squamous lung cancer.
Rossi A; Ricciardi S; Maione P; de Marinis F; Gridelli C
Lung Cancer; 2009 Nov; 66(2):141-9. PubMed ID: 19577816
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
Le Chevalier T
Semin Oncol; 2003 Aug; 30(4 Suppl 10):37-44. PubMed ID: 12947960
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed in the treatment of non-small cell lung cancer.
Shepherd FA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):43-8. PubMed ID: 12571810
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
Bunn PA
Semin Oncol; 2002 Jun; 29(3 Suppl 9):17-22. PubMed ID: 12094334
[TBL] [Abstract][Full Text] [Related]
9. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
Cohen MH; Justice R; Pazdur R
Oncologist; 2009 Sep; 14(9):930-5. PubMed ID: 19737998
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
Scagliotti GV
Lung Cancer; 2005 Oct; 50 Suppl 1():S18-9. PubMed ID: 16291426
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
Manegold C
Semin Oncol; 2003 Aug; 30(4 Suppl 10):32-6. PubMed ID: 12917819
[TBL] [Abstract][Full Text] [Related]
12. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Scagliotti G; Hanna N; Fossella F; Sugarman K; Blatter J; Peterson P; Simms L; Shepherd FA
Oncologist; 2009 Mar; 14(3):253-63. PubMed ID: 19221167
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
Hu X; Jiao S; Zhang S; Wang Z; Wang M; Huang C; Zheng R; Li K; Wang J; Wang Y; Ouyang X; Lv W; Cheng G; Hu C; Luo R; Sun Y
Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):569-75. PubMed ID: 23075680
[TBL] [Abstract][Full Text] [Related]
14. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Huang Y; Liu Y; Zhou J; Xu N; Li B; Wu G; Fang J; Li K; Liu X; Liu W; Lu Y; Wang M; Liu W; Liang H; Zhang Y; Huang C; Wang S; Wang Y; Yu S; Chang J; Wang Z; Hu Z; Zhang L
Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):576-82. PubMed ID: 23075681
[TBL] [Abstract][Full Text] [Related]
15. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
Bischoff HG; Heigener DF; Walzer S; Nuijten M
Lung Cancer; 2010 Aug; 69 Suppl 1():S18-23. PubMed ID: 20727458
[TBL] [Abstract][Full Text] [Related]
16. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Scagliotti G; Brodowicz T; Shepherd FA; Zielinski C; Vansteenkiste J; Manegold C; Simms L; Fossella F; Sugarman K; Belani CP
J Thorac Oncol; 2011 Jan; 6(1):64-70. PubMed ID: 21119545
[TBL] [Abstract][Full Text] [Related]
17. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
Paz-Ares LG; Altug S; Vaury AT; Jaime JC; Russo F; Visseren-Grul C
BMC Cancer; 2010 Mar; 10():85. PubMed ID: 20211022
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed in pancreatic cancer.
Kindler HL
Semin Oncol; 2002 Dec; 29(6 Suppl 18):49-53. PubMed ID: 12571811
[TBL] [Abstract][Full Text] [Related]
19. The evolving role of pemetrexed (Alimta) in lung cancer.
Socinski MA; Stinchcombe TE; Hayes DN
Semin Oncol; 2005 Apr; 32(2 Suppl 2):S16-22. PubMed ID: 15818533
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.
Simon GR; Manegold C; Barker SS; Treat JA; Visseren-Grul C; Obasaju C
Clin Lung Cancer; 2013 Nov; 14(6):601-8. PubMed ID: 23921171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
